Tempus secured a distribution agreement to roll out Predicta Biosciences’ GenoPredicta whole-genome sequencing assay for multiple myeloma. The lab-developed test is designed to identify high-risk patients using actionable DNA alterations from blood and bone marrow samples. GenoPredicta also supports minimal residual disease monitoring and clonal evolution tracking, with Tempus describing an ultrasensitive workflow that combines flow cytometry, cytogenetics, and whole-genome sequencing. Tempus said the test can detect biomarkers and phase variants using limited tumor cell inputs. The distribution deal is designed to broaden access to WGS-based decision-making for myeloma patients and to consolidate multiple testing modalities into one assessment. For precision oncology vendors, it reinforces the shift from imaging- and single-modality biomarker testing toward integrated genomic profiling. For sponsors, the agreement is a signal that WGS assays are becoming part of routine translational and clinical care workflows in hematologic cancers, supported by commercialization-oriented partnerships with clinical data platforms.